Abstract
Noninvasive imaging techniques like magnetic resonance imaging (MRI), computed tomography (CT) and single photon emission computed tomography (SPECT) play an increasingly important role in the diagnostic workup and treatment of cancerous disease. In this context, a distinct trend can be observed towards the development of contrast agents and radiopharmaceuticals that open up perspectives on a multimodality imaging approach, involving all three aforementioned techniques. To promote insight into the potentialities of such an approach, we prepared an overview of the strengths and limitations of the various imaging techniques, in particular with regard to their capability to quantify the spatial distribution of a multimodal diagnostic agent. To accomplish this task, we used a two-step approach. In the first step, we examined the situation for a particular therapeutic anti-cancer agent with multimodal imaging opportunities, viz. holmium- loaded microspheres (HoMS). Physical phantom experiments were performed to enable a comparative evaluation of the three modalities assuming the use of standard equipment, standard clinical scan protocols, and signal-known-exactly conditions. These phantom data were then analyzed so as to obtain first order estimates of the sensitivity and detection limits of MRI, CT and SPECT for HoMS. In the second step, the results for HoMS were taken as a starting point for a discussion of the factors affecting the sensitivity and detection limits of MRI, CT and SPECT for multimodal agents in general. In this, emphasis was put on the factors that must be taken into account when extrapolating the findings for HoMS to other diagnostic tasks, other contrast agents, other experimental conditions, and other scan protocols.
Keywords: detection limits, sensitivity, holmium, SPECT, CT, MRI, contrast agent, Multimodal imaging
Anti-Cancer Agents in Medicinal Chemistry
Title: Factors Affecting the Sensitivity and Detection Limits of MRI, CT, and SPECT for Multimodal Diagnostic and Therapeutic Agents
Volume: 7 Issue: 3
Author(s): Peter R. Seevinck, Jan-Henry Seppenwoolde, Tim C. de Wit, Johannes F. W. Nijsen, Freek J. Beekman, Alfred D. van het Schip and Chris J. G. Bakker
Affiliation:
Keywords: detection limits, sensitivity, holmium, SPECT, CT, MRI, contrast agent, Multimodal imaging
Abstract: Noninvasive imaging techniques like magnetic resonance imaging (MRI), computed tomography (CT) and single photon emission computed tomography (SPECT) play an increasingly important role in the diagnostic workup and treatment of cancerous disease. In this context, a distinct trend can be observed towards the development of contrast agents and radiopharmaceuticals that open up perspectives on a multimodality imaging approach, involving all three aforementioned techniques. To promote insight into the potentialities of such an approach, we prepared an overview of the strengths and limitations of the various imaging techniques, in particular with regard to their capability to quantify the spatial distribution of a multimodal diagnostic agent. To accomplish this task, we used a two-step approach. In the first step, we examined the situation for a particular therapeutic anti-cancer agent with multimodal imaging opportunities, viz. holmium- loaded microspheres (HoMS). Physical phantom experiments were performed to enable a comparative evaluation of the three modalities assuming the use of standard equipment, standard clinical scan protocols, and signal-known-exactly conditions. These phantom data were then analyzed so as to obtain first order estimates of the sensitivity and detection limits of MRI, CT and SPECT for HoMS. In the second step, the results for HoMS were taken as a starting point for a discussion of the factors affecting the sensitivity and detection limits of MRI, CT and SPECT for multimodal agents in general. In this, emphasis was put on the factors that must be taken into account when extrapolating the findings for HoMS to other diagnostic tasks, other contrast agents, other experimental conditions, and other scan protocols.
Export Options
About this article
Cite this article as:
Seevinck R. Peter, Seppenwoolde Jan-Henry, de Wit C. Tim, W. Nijsen F. Johannes, Beekman J. Freek, van het Schip D. Alfred and G. Bakker J. Chris, Factors Affecting the Sensitivity and Detection Limits of MRI, CT, and SPECT for Multimodal Diagnostic and Therapeutic Agents, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618153
DOI https://dx.doi.org/10.2174/187152007780618153 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Lignans from Medicinal Plants and their Anticancer Effect
Mini-Reviews in Medicinal Chemistry Genomics and Public Health Research: Building Public “Goods”? Divergences and Convergences of Views in Four Stakeholder Groups
Current Pharmacogenomics and Personalized Medicine Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy
Mini-Reviews in Medicinal Chemistry Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: Molecular Mechanisms of Action
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Development of Drug Targeting and Delivery in Cervical Cancer
Current Cancer Drug Targets Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience Recent Improvements in the Use of Synthetic Peptides for a Selective Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Discovery and Hit to Lead Optimization of Novel Combretastatin A-4 Analogues: Dependence of C-Linker Length and Hybridization
Anti-Cancer Agents in Medicinal Chemistry